Literature DB >> 5348877

Treatment of hypertension with hydrochlorothiazide and spironolactone.

R I Ogilvie, J Ruedy.   

Abstract

A comparison was made of the antihypertensive effect of a daily dose of 150 mg. of hydrochlorothiazide (HCT) with one of 150 mg. of spironolactone (SL) in 48 patients with essential hypertension.The blood pressure values after six weeks of therapy with HCT were not significantly different from those after SL. Treatment of 25 of these patients with the two agents combined did not reduce the blood pressure further. Blood urea nitrogen concentrations increased with both HCT and SL treatment.With combined treatment there was a further increase in blood urea nitrogen concentration and a decrease in serum sodium concentrations without weight loss beyond that achieved with either HCT or SL alone.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5348877      PMCID: PMC1946539     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  2 in total

1.  Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together.

Authors:  B M Winer; W F Lubbe; T Colton
Journal:  JAMA       Date:  1968-05-27       Impact factor: 56.272

2.  Changes in plasma renin activity after administration of spironolactone.

Authors:  M Maebashi; K Yoshinaga
Journal:  Jpn Circ J       Date:  1967-03
  2 in total
  3 in total

1.  Renin concentrations and effects of propranolol and spironolactone in patients with hypertension.

Authors:  B E Karlberg; B Kågedal; L Tegler; K Tolagen
Journal:  Br Med J       Date:  1976-01-31

2.  Saturable kinetics of intravenous chlorothiazide in the rhesus monkey.

Authors:  J H Gustafson; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

3.  Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.

Authors:  Timo P Hiltunen; Jenni M Rimpelä; Robert P Mohney; Steven M Stirdivant; Kimmo K Kontula
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.